Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 18/20 | 0.49 |
| ▸ | GAA | P10253 | 15/20 | 0.49 |
| ▸ | TP53 | P04637 | 8/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14016045 | 0.90 | MAPT (0.46) | MAPTGAATP53SMN1; SMN2KMT2A | |
| SCHEMBL2252293 | 0.88 | MAPT (0.54) | MAPTGAATP53SMN1; SMN2KMT2A | |
| SCHEMBL2254347 | 0.86 | MAPT (0.49) | MAPTGAATP53SMN1; SMN2KMT2A | |
| SCHEMBL2252270 | 0.85 | MAPT (0.55) | MAPTGAATP53SMN1; SMN2KMT2A | |
| SCHEMBL2252362 | 0.84 | MAPT (0.65) | MAPTGAATP53SMN1; SMN2KMT2A | |
| SCHEMBL2252246 | 0.84 | MAPT (0.47) | MAPTGAATP53SMN1; SMN2KMT2A | |
| SCHEMBL2253486 | 0.82 | MAPT (0.51) | MAPTGAATP53SMN1; SMN2KMT2A | |
| SCHEMBL2253450 | 0.81 | MAPT (0.51) | MAPTGAATP53SMN1; SMN2KMT2A | |
| SCHEMBL2256827 | 0.81 | GAA (0.68) | MAPTGAATP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL14016031 | 0.79 | MAPT (0.70) | MAPTGAATP53SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155747-B1 | IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS | GE HEALTHCARE LTD (GB) | 2012-10-24 | — | — | EP | disclosed |
| US-20110206607-A1 | IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS | GE HEALTHCARE LIMITED (GB) | 2011-08-25 | — | — | US | disclosed |
| US-20110206607-A1 | IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS | GE HEALTHCARE LIMITED (GB) | 2011-08-25 | — | — | US | disclosed |
| US-20110206607-A1 | IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS | GE HEALTHCARE LIMITED (GB) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110206607-A1 | IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS | CNR1, CNR2, GPR18 | MAPT 2915/4885GAA 4087/4885TP53 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.